Results 261 to 270 of about 167,880 (309)
Some of the next articles are maybe not open access.
Diabetes Research and Clinical Practice, 2018
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. It is the first line pharmacotherapy for glucose control in patients with Type 2 diabetes due to its safety, efficacy and tolerability.
Ritwika, Mallik, Tahseen A, Chowdhury
openaire +2 more sources
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. It is the first line pharmacotherapy for glucose control in patients with Type 2 diabetes due to its safety, efficacy and tolerability.
Ritwika, Mallik, Tahseen A, Chowdhury
openaire +2 more sources
Drugs of Today, 2008
Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today. Despite low potency and a long list of contraindications, metformin has remained successful and even expanded experimental use due to its ...
openaire +2 more sources
Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today. Despite low potency and a long list of contraindications, metformin has remained successful and even expanded experimental use due to its ...
openaire +2 more sources
Regulatory Toxicology and Pharmacology, 2018
This review investigates the different biological effect of Metformin (MET) in different conditions. MET is an oral antidiabetic drug used for the treatment of type 2 diabetes mellitus (T2DM) particularly in overweight people. The main mechanism of action of the MET is inhibition of hepatic glucose production and reduction of insulin resistance.
Tuğba Adak +3 more
openaire +3 more sources
This review investigates the different biological effect of Metformin (MET) in different conditions. MET is an oral antidiabetic drug used for the treatment of type 2 diabetes mellitus (T2DM) particularly in overweight people. The main mechanism of action of the MET is inhibition of hepatic glucose production and reduction of insulin resistance.
Tuğba Adak +3 more
openaire +3 more sources
European Journal of Emergency Medicine, 2009
info:eu-repo/semantics ...
Lheureux, Philippe +2 more
openaire +2 more sources
info:eu-repo/semantics ...
Lheureux, Philippe +2 more
openaire +2 more sources
Annals of Internal Medicine, 2002
Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties. Its efficacy in reducing hyperglycemia in type 2 diabetes mellitus is similar to that of sulfonylureas, thiazolidinediones, and insulin. Metformin-based combination therapy is often superior to therapy with a single hypoglycemic agent.
Dmitri, Kirpichnikov +2 more
openaire +2 more sources
Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties. Its efficacy in reducing hyperglycemia in type 2 diabetes mellitus is similar to that of sulfonylureas, thiazolidinediones, and insulin. Metformin-based combination therapy is often superior to therapy with a single hypoglycemic agent.
Dmitri, Kirpichnikov +2 more
openaire +2 more sources
Drugs, 2006
A fixed-dose pioglitazone/metformin tablet is approved in the US and the EU for the treatment of adult patients with type 2 diabetes mellitus who currently have inadequate glycaemic control with metformin monotherapy. In the US, the combination tablet is also approved for the treatment of adult patients with type 2 diabetes who currently have ...
Emma D, Deeks, Lesley J, Scott
openaire +2 more sources
A fixed-dose pioglitazone/metformin tablet is approved in the US and the EU for the treatment of adult patients with type 2 diabetes mellitus who currently have inadequate glycaemic control with metformin monotherapy. In the US, the combination tablet is also approved for the treatment of adult patients with type 2 diabetes who currently have ...
Emma D, Deeks, Lesley J, Scott
openaire +2 more sources
General Pharmacology: The Vascular System, 1993
Metformin (dimethylbiguanide) is an antihyperglycaemic drug used to treat non-insulin dependent diabetes mellitus. It acts in the presence of insulin to increase glucose utilization and reduce glucose production, thereby countering insulin resistance.
openaire +2 more sources
Metformin (dimethylbiguanide) is an antihyperglycaemic drug used to treat non-insulin dependent diabetes mellitus. It acts in the presence of insulin to increase glucose utilization and reduce glucose production, thereby countering insulin resistance.
openaire +2 more sources
Diabetes & Metabolism, 2014
These case reports demonstrate that, at the individual level, blood metformin concentrations and metformin effects on lactate do not always correlate.We report here on two unusual cases: metformin accumulation in the absence of hyperlactataemia; and metformin-induced hyperlactataemia with no metformin accumulation.Patient #1 presented with severe ...
J D, Lalau +4 more
openaire +2 more sources
These case reports demonstrate that, at the individual level, blood metformin concentrations and metformin effects on lactate do not always correlate.We report here on two unusual cases: metformin accumulation in the absence of hyperlactataemia; and metformin-induced hyperlactataemia with no metformin accumulation.Patient #1 presented with severe ...
J D, Lalau +4 more
openaire +2 more sources
Clinical Pharmacokinetics of Metformin
Clinical Pharmacokinetics, 2011Metformin is widely used for the treatment of type 2 diabetes mellitus. It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hydrophilic base which exists at physiological pH as the cationic species (>99.9%). Consequently, its passive diffusion through cell membranes should be
Graham, Garry G. +12 more
openaire +5 more sources